Literature DB >> 28616936

Encephaloduroateriosynangiosis (EDAS) in the management of Moyamoya syndrome in children with sickle cell disease.

Alexander Alamri1, Pennylouise Hever1, Jebet Cheserem1, Catia Gradil1, Sanj Bassi1, Christos M Tolias1.   

Abstract

BACKGROUND: Encephalo-duro-arterio-synangiosis (EDAS) in Moyamoya syndrome (MMS) treatment has been well described in the literature, however in MMS caused by sickle cell anaemia (SCA), EDAS use remains controversial with poor long-term follow-up. We present a case-series of SCA patients who have undergone EDAS for SCA-related MMS and describe their post-operative course as well as provide a literature review of the role of EDAS in the treatment of sickle cell anaemia.
METHODS: A retrospective review of all the paediatric EDAS procedures conducted in our institution for SCA from 2007 to 2015. Two patients underwent behavioural screening.
RESULTS: A total of eight patients with MMS secondary to SCA underwent EDAS. Unilateral EDAS was performed without complication in seven patients. One patient underwent bilateral EDAS but with a two-year gap in between procedures. Follow-up magnetic resonance angiography demonstrated no progression of Moyamoya collaterals or further ischaemic events with regression of collaterals clearly visible in one patient. All patients have demonstrated a return to normal school activities.
CONCLUSIONS: EDAS is a well-tolerated revascularisation procedure for children with MMS. The prevention of further infarcts in our group with sickle cell disease has allowed these children to resume normal school activities.

Entities:  

Keywords:  Encephaloduroarteriosynangiosis; Moyamoya syndrome; children; sickle cell

Mesh:

Year:  2017        PMID: 28616936     DOI: 10.1080/02688697.2017.1339227

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  3 in total

1.  Microduplication of 15q13.3 and Microdeletion of 18q21.32 in a Patient with Moyamoya Syndrome.

Authors:  Sciacca Francesca Luisa; Ambra Rizzo; Gloria Bedini; Fioravante Capone; Vincenzo Di Lazzaro; Sara Nava; Francesco Acerbi; Davide Sebastiano Rossi; Simona Binelli; Giuseppe Faragò; Andrea Gioppo; Marina Grisoli; Maria Grazia Bruzzone; Paolo Ferroli; Chiara Pantaleoni; Luigi Caputi; Jesus Vela Gomez; Eugenio Agostino Parati; Anna Bersano
Journal:  Int J Mol Sci       Date:  2018-11-20       Impact factor: 5.923

2.  The contralateral progression in a cohort of Chinese adult patients with unilateral moyamoya disease after revascularization: a single-center long-term retrospective study.

Authors:  Xiao Tian; Miao Hu; Jianjian Zhang
Journal:  Acta Neurochir (Wien)       Date:  2022-03-26       Impact factor: 2.816

3.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.